Sight Sciences, Inc. SGHT
We take great care to ensure that the data presented and summarized in this overview for Sight Sciences, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SGHT
View all-
Kck Ltd. Tortola, D84.37MShares$18.6 Million100.0% of portfolio
-
Long Focus Capital Management, LLC San Juan, PR3.15MShares$13.4 Million0.6% of portfolio
-
Black Rock Inc. New York, NY2.12MShares$9.01 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.8MShares$7.67 Million0.0% of portfolio
-
B Group, Inc. Dallas, TX930KShares$3.95 Million2.96% of portfolio
-
Prosight Management, LP Dallas, TX872KShares$3.7 Million0.98% of portfolio
-
Americana Partners, LLC Houston, TX864KShares$3.67 Million0.14% of portfolio
-
Geode Capital Management, LLC Boston, MA846KShares$3.59 Million0.0% of portfolio
-
Apollo Management Holdings, L.P. New York, NY672KShares$2.85 Million0.06% of portfolio
-
State Street Corp Boston, MA654KShares$2.78 Million0.0% of portfolio
Latest Institutional Activity in SGHT
Top Purchases
Top Sells
About SGHT
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
Insider Transactions at SGHT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 17
2025
|
David Badawi Chief Technology Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+2.09%
|
$0
$0.12 P/Share
|
|
Jul 03
2025
|
Jeremy B. Hayden Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
9,160
-3.33%
|
$36,640
$4.17 P/Share
|
|
Jul 03
2025
|
David Badawi Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
5,679
-0.31%
|
$22,716
$4.17 P/Share
|
|
Jul 02
2025
|
Alison Bauerlein Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
19,260
-3.02%
|
$77,040
$4.1 P/Share
|
|
Jul 02
2025
|
Matthew Link Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
4,889
-0.58%
|
$19,556
$4.1 P/Share
|
|
Jul 01
2025
|
Paul Badawi President and CEO |
SELL
Open market or private sale
|
Direct |
23,637
-0.39%
|
$94,548
$4.15 P/Share
|
|
Jun 06
2025
|
Staffan Encrantz |
BUY
Open market or private purchase
|
Direct |
27,900
+1.98%
|
$111,600
$4.22 P/Share
|
|
Jun 05
2025
|
Catherine Mazzacco |
BUY
Grant, award, or other acquisition
|
Direct |
30,952
+28.28%
|
-
|
|
Jun 05
2025
|
Brenda Jane Larsen Becker |
BUY
Grant, award, or other acquisition
|
Direct |
30,952
+28.14%
|
-
|
|
Jun 05
2025
|
Donald Zurbay |
BUY
Grant, award, or other acquisition
|
Direct |
30,952
+15.77%
|
-
|
|
Jun 05
2025
|
Tamara Fountain |
BUY
Grant, award, or other acquisition
|
Direct |
30,952
+27.55%
|
-
|
|
Jun 05
2025
|
Erica J. Rogers |
BUY
Grant, award, or other acquisition
|
Direct |
30,952
+15.0%
|
-
|
|
Jun 05
2025
|
Staffan Encrantz |
BUY
Grant, award, or other acquisition
|
Direct |
30,952
+2.24%
|
-
|
|
Jun 05
2025
|
Staffan Encrantz |
BUY
Open market or private purchase
|
Direct |
40,951
+3.01%
|
$163,804
$4.24 P/Share
|
|
Jun 04
2025
|
Staffan Encrantz |
BUY
Open market or private purchase
|
Direct |
21,674
+1.67%
|
$86,696
$4.17 P/Share
|
|
Jun 03
2025
|
Staffan Encrantz |
BUY
Open market or private purchase
|
Direct |
25,230
+1.97%
|
$75,690
$3.97 P/Share
|
|
Jun 02
2025
|
Staffan Encrantz |
BUY
Open market or private purchase
|
Direct |
30,799
+2.44%
|
$92,397
$3.88 P/Share
|
|
May 30
2025
|
Staffan Encrantz |
BUY
Open market or private purchase
|
Direct |
42,753
+3.44%
|
$128,259
$3.67 P/Share
|
|
May 29
2025
|
Staffan Encrantz |
BUY
Open market or private purchase
|
Direct |
60,128
+4.94%
|
$180,384
$3.59 P/Share
|
|
May 28
2025
|
Staffan Encrantz |
BUY
Open market or private purchase
|
Direct |
26,715
+2.38%
|
$80,145
$3.52 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 1.62M shares |
|---|---|
| Other acquisition or disposition | 513K shares |
| Open market or private purchase | 904K shares |
| Exercise of conversion of derivative security | 40K shares |
| Open market or private sale | 883K shares |
|---|---|
| Payment of exercise price or tax liability | 12K shares |